Newbury Pharmaceuticals AB

NEWBRY

SE0015244884

Drug Retailers

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-28 pm EDT			5-day change	1st Jan Change
3.22 ^SEK	-3.01%		-6.94%	+4.89%

Jun. 20	Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen	CI
Apr. 10	Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI

Newbury Pharmaceuticals AB Provides Earnings Guidance for the Year 2028

June 16, 2023 at 03:42 am EDT

Newbury Pharmaceuticals AB (publ) provided earnings guidance for the year 2028. For the period, the company expects to achieve sales of SEK 350 million.

Latest news about Newbury Pharmaceuticals AB

Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen	Jun. 20	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 10	CI
Newbury Pharmaceuticals Secures SEK9 Million Sales Order	Feb. 22	MT
Newbury Pharmaceuticals Receives International Sales Order Valued At 8.8 Million	Feb. 22	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 10	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Full Year Ended August 31, 2023	23-10-11	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	23-10-11	CI
Newbury, Amarox Sign Distribution Deal for Sweden, Denmark	23-10-06	MT
Newbury Signs Contract with Amarox Limited to Represent and Distribute Their Products in Sweden and Denmark	23-10-06	CI
Newbury Pharmaceuticals Strengthens its Portfolio with Levodopa/Benserazide	23-09-22	CI
Newbury Secures Access to Hospital Product Portfolio in New Partnership	23-08-23	MT
Newbury Pharmaceuticals AB Gains Access to the Nordic Hospital Market with A New Strategic Partnership for Prescription Medicine	23-08-23	CI
Newbury Pharmaceuticals Gets OK to Sell Peptide Product in Sweden	23-07-19	MT
Newbury Pharmaceuticals Announces the Marketing Authorization of Desmopressin Newbury 60, 120 & 240 Mg Sublingual Tablets in Sweden	23-07-19	CI
Newbury Pharmaceuticals AB Provides Earnings Guidance for the Year 2028	23-06-16	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-06-14	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-12	CI
Newbury Pharmaceuticals Announces the Marketing Authorization of Lapatinib Newbury 250 Mg Film-Coated Tablets in Sweden	23-03-24	CI
Newbury Pharmaceuticals' MS Treatment Receives Marketing Authorization in Sweden	23-03-06	MT
Newbury Pharmaceuticals Announces the Marketing Authorization of Dimethyl Fumarate Newbury 120 & 240 Mg Hard Capsule in Sweden	23-03-06	CI
Certain Ordinary Shares of Newbury Pharmaceuticals AB are subject to a Lock-Up Agreement Ending on 27-JAN-2023.	23-01-26	CI
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-11	CI
Newbury Pharmaceuticals Receives Orders for International Markets Covering Shipments During 2023	23-01-09	CI
Newbury Pharmaceuticals Gets Marketing Approval in Sweden for Multiple Sclerosis Drug	22-12-27	MT
Newbury Expands Its Portfolio with Two Ready to Launch Products	22-11-23	CI

Chart Newbury Pharmaceuticals AB

Duration

Period

More charts

Newbury Pharmaceuticals AB is a Sweden-based pharmaceutical company for specialty prescription drugs. The Companyâs existing portfolio is focused on the Scandinavian market and consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology.

Sector

Drug Retailers

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Retail - Drugs without Grocery

	1st Jan change	Capi.
NEWBURY PHARMACEUTICALS AB	+4.89%	7.37M
RAIA DROGASIL S.A.	-12.65%	7.93B
AIN HOLDINGS INC.	+33.84%	1.3B
QOL HOLDINGS CO., LTD.	-9.90%	346M
NIHON CHOUZAI CO.,LTD.	+6.86%	278M
SALUS, LJUBLJANA, D. D.	+9.44%	222M
GREEN CROSS HEALTH LIMITED	-34.86%	62.09M
MEDICAL IKKOU GROUP CO.,LTD.	+26.51%	60.97M

Retail - Drugs without Grocery

Newbury Pharmaceuticals AB

Equities

NEWBRY

SE0015244884

Drug Retailers

Newbury Pharmaceuticals AB Provides Earnings Guidance for the Year 2028

Latest news about Newbury Pharmaceuticals AB

Chart Newbury Pharmaceuticals AB

Company Profile

Income Statement Evolution

Chiffre d''affaires - Rate of surprise

Sector Retail - Drugs without Grocery